Astrana Health Soars on Record Revenue, Stumbles on Accounting Controls

ALHAMBRA, Calif. – March 02, 2026 – Astrana Health, Inc. (NASDAQ: ASTH) today presented a picture of robust growth and operational success, announcing record-breaking financial results for 2025, fueled by major acquisitions and its technology-driven approach to value-based care. The company reported a staggering 56% year-over-year revenue increase to $3.18 billion. However, the triumphant announcement was tempered by a significant disclosure: a "material weakness" in its internal financial controls, which will delay the official filing of its annual report with the Securities and Exchange Commission.

In a statement, President and CEO Brandon Sim celebrated the company's performance, attributing it to the company's unique business model. "Astrana delivered record revenue, adjusted EBITDA, and free cash flow in 2025, demonstrating the strength and predictability of our fully delegated, payer-agnostic care model and AI-enabled technology platform in a dynamic operating environment," Sim said. He projected continued strong growth for 2026, with the integration of its recent Prospect Health acquisition running "ahead of schedule."

A Year of Explosive Growth

The financial figures released by Astrana paint a compelling portrait of a company in high-growth mode. Full-year 2025 revenue hit $3.18 billion, a significant leap from $2.03 billion in the prior year. The company's core Care Partners segment was the primary driver, with revenue jumping 55% to over $3 billion. Adjusted EBITDA, a key measure of profitability, rose 21% to $205.4 million for the year.

The fourth quarter of 2025 also showed strong momentum, with total revenue of $950.5 million, up 43% from the same period in 2024, and adjusted EBITDA surging 50% to $52.5 million. This performance has emboldened the company to issue strong guidance for 2026, projecting total revenue in the range of $3.8 billion to $4.1 billion and adjusted EBITDA between $250 million and $280 million.

Much of this growth can be traced to Astrana's aggressive acquisition strategy, most notably the completed acquisition of Prospect Health in July 2025. The $708 million deal massively expanded Astrana's footprint, adding over 11,000 providers and 600,000 patients across several states. Astrana estimates the acquisition will contribute approximately $1.2 billion in annual revenue, and the company is confident it will achieve up to $15 million in annualized synergies.

A Shadow on the Balance Sheet

Despite the stellar financial performance, a concerning footnote accompanied the release. Astrana announced it would be filing for a 15-day extension for its annual Form 10-K report due to the discovery of a "material weakness in internal control over financial reporting." The company specified the weakness relates to its "acquisition and purchase accounting processes"—a critical area for a company whose growth is heavily dependent on M&A.

While Astrana was quick to assure investors that the issue "does not reflect any material misstatement of the Company's financial results, nor does it result in any restatements of historical periods," such disclosures are a significant red flag for investors and regulators. A material weakness indicates that a company's procedures are not sufficient to prevent or detect a significant error in its financial statements in a timely manner.

Historically, the market reacts negatively to news of filing delays tied to accounting issues. Studies have shown that announcements of 10-K tardiness can cause an average stock price drop of around 2%, with a more pronounced decline when internal control problems are cited. These disclosures can lead to increased audit fees, heightened SEC scrutiny, and a potential erosion of investor confidence. The issue is particularly acute when related to complex transactions like mergers and acquisitions, where proper accounting is paramount. Astrana has stated it is making "targeted investments in our accounting organization to accelerate remediation."

The AI-Powered Value-Based Care Engine

At the heart of Astrana's growth narrative is its physician-centric, AI-powered platform, designed to optimize value-based care. This model shifts the focus from the quantity of services provided to the quality of patient outcomes. The company supports over 20,000 providers by embedding its proprietary technology directly into their workflows.

According to the company, this technology provides real-time insights, automates administrative tasks, and helps manage patient populations more effectively. For instance, Astrana reports that its platform automatically processes over two-thirds of prior authorizations, a notorious bottleneck in the healthcare system. The results appear tangible: the company claims providers who are highly engaged with its platform achieve a 24% higher care-gap closure rate and a 30% higher rate of completing Annual Wellness Visits.

This focus on technology-driven efficiency and profitability sets Astrana apart from some peers in the value-based care space. For example, while competitor agilon health reported higher total revenue in 2025, it also posted a significant adjusted EBITDA loss. Astrana’s positive adjusted EBITDA and free cash flow of $104.5 million suggest its model is proving to be more financially sustainable so far.

Capital Confidence and Future Outlook

In a strong vote of confidence for its own future, Astrana's Board of Directors announced it was doubling its share repurchase program from $50 million to $100 million. This move, which allows the company to buy back its own stock on the open market, signals that management believes the shares are undervalued and is confident in its long-term cash generation capabilities. During the fourth quarter of 2025, the company already repurchased over 633,000 shares.

The expanded buyback, combined with the aggressive growth strategy, paints a picture of a company balancing rapid expansion with a commitment to delivering shareholder value. While smaller than industry behemoths like UnitedHealth Group or CVS Health, Astrana is carving out a significant and profitable niche. The immediate challenge for the company will be to swiftly remediate its internal control issues and file its delayed 10-K, proving to the market that its accounting practices are as robust as its growth engine. The coming weeks will be critical in determining whether investors focus on the record-breaking revenue or the procedural misstep that accompanied it.